

In Vitro Potency

Kinase Targets

Eurofins Pharma Discovery Services has a broad and continuously expanding portfolio of recombinant proteins including active, inactive and unactivated kinases, phosphatases and the largest available selection of disease relevant mutants. The KinaseProfiler™ selectivity profiling service accelerates your discoveries with:

- A 1-week guarantee, the industry's quickest turnaround time
- Complete flexibility—single target SAR to full panel screens
- Gold standard radiometric protein kinase assays
- Consistently ranked as the most preferred and used kinase profiling CRO for Pharma by independent market research¹

Epigenetic Targets

Epigenetics is becoming an increasingly important realm for oncology therapies. Indeed, several drugs directed towards epigenetic modifying enzymes are already on the market with more in the clinic to treat cancer. Eurofins Epigenetic Screening and Profiling Service gives you access to over 160 assays in our broad and diverse portfolio of targets including:

- 50+ Writers
- 40+ Erasers
- 45+ Readers
- Biologically-relevant co-factors and substrates
- Access to multiple technologies, including:
 - Gold standard radiometric
 - Mass spectrometry
 - TR-FRET assays

OncoPanel™ Cell-Based Profiling Service


The OncoPanel™ Cell-Based Profiling Service enables identification of predictive genomic biomarkers to facilitate patient stratification and drug response data across a genomically diverse set of 300 cancer cell lines. Small molecules and biologics may be tested in the entire panel of 300 cell lines or researchers may select any subset of cell lines to test their compounds of interest.

- Several conditions available: 2D, 3D, long-term culture, drug combination, biologics
- Available data points include: cell proliferation, apoptosis, cell cycle, custom markers
- All cell lines are licensed
- Cell identity confirmed by STR analysis
- Cell performance tracked since 2009

Cell Type	2D Culture
Bladder	11
Breast	18
Central Nervous System	24
Colon	30
Endocrine	7
Eye	1
Female GU	20
Haematopoietic	57
Head and Neck	12
Kidney	10
Liver	7
Lung	23
Pancreas	13
Placenta	3
Prostate	6
Skin	25
Soft Tissue	25
Stomach	7
Testis	1
	300

Built upon the expertise of
Eurofins Discovery Services, Cerep & Panlabs

For more information visit:
eurofins.com/epds



475+
Kinase and Epigenetic Assays

40+
Years of Experience
with In Vitro Safety

15+
Years Providing
ADME-Tox Assays

20+
Years Providing
Cell-Based Assays

900+
In Vitro Safety Assays

30+
Years of Experience
with In Vivo Models

In Vitro Safety

Eurofins Pharma Discovery Services provides you critical, early assessment across a range of targets through our broad offering of safety and toxicity services. Our functional assays provide you with more biologically relevant data, empowering you to make better decisions.

- Target based selectivity profiling including our CardiacProfiler™, SafetyScreen44™ and SafetyScreen87™
- Cell based phenotypic assays covering:
 - Cytotoxicity, cardiotoxicity, hepatotoxicity, immunotoxicity and genotoxicity
- Assays for Drug-drug interactions



In Vivo Safety & Efficacy

The in vivo oncology services from Eurofins Pharma Discovery Services enables the evaluation of therapeutics starting with safety/tolerability and pharmacokinetic (PK) models prior to testing for efficacy with xenograft or syngeneic models. All studies have protocols written and reviewed by a highly experienced team of Technical and Study Directors.

- 15 xenograft models, representing 13 cancer tissues
- Syngeneic models for three different cancer tissues
- Laboratory staff with average experience of 15 years
- Custom models developed on request



ADME-Tox

Eurofins Pharma Discovery Services has state-of-the-art bioanalytic equipment to generate ADME-Tox data for the advancement of a drug candidate in the discovery process. Assays include but aren't limited to:

- Metabolic Stability
- CYP Inhibition/Induction
- Permeability
- Solubility
- Protein Binding
- Drug Transporters
- CYP Phenotyping
- UGT
- Metabolite Identification
- Blood/Plasma Stability
- Blood Partitioning
- Analytical Method Development
- Quantitative Bioanalysis
- Cardiotoxicity
- Cytotoxicity
- Genotoxicity

¹ "Most Preferred and Most Used fee-for-service supplier in the Pharma Industry survey segment." - Kinase Screening & Profiling Trends, HTStec Limited, 2013

Flex Lab™ Custom Services

Recombinant Protein Products

Research and Drug Discovery projects are challenging. Wouldn't it be great if you didn't have to worry about your proteins? Eurofins Pharma Discovery Services has over two decades experience in manufacturing proteins for a variety of your research and Drug Discovery needs. Leverage our deep understanding of how to design, produce and purify active proteins so you don't have to be concerned with:

- Finding consistent, high quality proteins from small to HTS scale
- Working with a partner that can assist you with assay development
- Overcoming the challenges associated with generating complex targets
- Obtaining fully functional proteins that work in binding and activity assays
- Collaborating with a partner who truly understands the drug discovery process

Custom Assay Development

As specialists in assay development, Eurofins Pharma Discovery Services offers Custom Assay Development when standard catalog assays do not meet a client's specific needs. Custom assay development may include simple modifications to existing assays or de novo assay development that can be transferred to a client's laboratory. All projects are conducted in a collaborative manner with specific decision points for the client to monitor the progress of each project. Assays include:

- Binding and Enzyme kinetics
- Molecular Interactions
- Protein Expression and Purification



For more information visit: eurofins.com/epds

**Built upon the expertise of
Eurofins Discovery Services, Cerep, Panlabs &
Villapharma**

For current contact details related to each of our global locations,
please reference our website: eurofins.com/epdslocations